Prof Fabrice Andre talks to ecancer about identifying patients with a high risk of recurrence at IMPAKT 2012 in Brussels, May 2012.
The importance of identifying high risk patients is not just discovering which are the most susceptible to relapse, but to avoid giving a patient a therapy that will have a low effect as well.
Prof Andre notes that by using protein based and prognostic biomarkers, the best possible therapy with the lowest risk of relapse, can be identified.
The second challenge that Prof Andre addresses is how to bridge the gap between research settings and clinical practice.
Filming Supported by Amgen